MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis

Justin D. Glenn, Itzy Morales Pantoja, Patrizio Caturegli, Katharine A. Whartenby

Research output: Contribution to journalArticlepeer-review

Abstract

Multiple sclerosis (MS) is an autoimmune disease that remains in need of effective therapies. Plant-derived medicines have appealing properties for the treatment of autoimmune diseases. MYMD-1 is a synthetic plant alkaloid that has been shown to ameliorate the course of autoimmune thyroiditis. The goal of the present study was to determine whether MYMD-1 would produce similar beneficial effects in a mouse model of MS, experimental autoimmune encephalomyelitis (EAE) induced by immunization with myelin oligodendrocyte glycoprotein. MYMD-1 improved the course of EAE and suppressed activation of effector T cells without causing global immunosuppression or toxicity. These results suggest that MYMD-1 may be of interest for evaluating for the treatment of autoimmune diseases.

Original languageEnglish (US)
Article number577115
JournalJournal of Neuroimmunology
Volume339
DOIs
StatePublished - Feb 15 2020

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'MYMD-1, a novel alkaloid compound, ameliorates the course of experimental autoimmune encephalomyelitis'. Together they form a unique fingerprint.

Cite this